WILMINGTON, Del., April 7 /PRNewswire/ -- Cancer researchers led by Bruce Boman, M.D., Ph.D. director of Cancer Genetics and Stem Cell Biology at the Helen F. Graham Cancer Center of the Christiana Care Health System, and a faculty member at the University of Delaware, have discovered an enzyme common to both normal and malignant colon stem cells that will assist scientists searching for a cure for colon cancer.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090407/DC95299LOGO )
To date, knowledge of a substance, often referred to as a marker, that enables doctors to identify, locate, and isolate normal and malignant colon stem cells, has been elusive. But the discovery by Dr. Boman and colleagues that aldehyde dehydrogenase 1 (ALDH1) is a marker for identifying and isolating colon stem cells is a potential breakthrough in the search for a key to what drives colon cancer growth.
"This is a very important tool for future research," said Boman, M.D., Ph.D., M.S.P.H., and F.A.C.P., who is also a professor of Medical Oncology at Thomas Jefferson University. "Finding a better way to identify, isolate, and track colon cancer stem cells moves us one step closer to understanding what drives tumor growth and to developing new treatments for advanced colon cancer and ways to prevent colon cancer from developing in the first place."
Dr. Boman adds that his team decided to focus on ALDH1 because it had previously been identified as a marker for leukemias, brain cancers, and breast cancer. The researchers found that ALDH1 is a more specific marker for colon cancer stem cells than are other previously identified candidate markers.
In the study, researchers implanted into mice colon stem cells from seven patients diagnosed with colon cancer, and found that the number of ALDH1 cells inc
Page: 1 2 Related medicine technology :1
|SOURCE Christiana Care Health System|
Copyright©2009 PR Newswire.
All rights reserved
. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria2
. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs3
. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals4
. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies5
. ARCA Discovery Announces Data Demonstrating Potential for Bucindolol as Targeted Therapy in Heart Failure, Atrial Fibrillation, and Ventricular Arrhythmia6
. Five Clinical Studies to Receive $2.5 Million Under Foundations 2007 Clinical Discovery Program7
. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.8
. FASgen Announces New Discovery for Treatment of Stroke9
. Nobel Prize-Winning Discovery10
. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers11
. FASgen Announces a New Discovery in Obesity Research